Helius Medical Technologies (HSDT) EPS Estimated At $0.00; Enteromedics (ETRM) Shorts Up By 2.59%

June 20, 2017 - By Clifton Ray

Enteromedics Incorporated (NASDAQ:ETRM) had an increase of 2.59% in short interest. ETRM’s SI was 931,900 shares in June as released by FINRA. Its up 2.59% from 908,400 shares previously. With 357,500 avg volume, 3 days are for Enteromedics Incorporated (NASDAQ:ETRM)’s short sellers to cover ETRM’s short positions. The SI to Enteromedics Incorporated’s float is 13.58%. The stock increased 1.45% or $0.07 on June 19, reaching $4.91. About shares traded. EnteroMedics Inc (NASDAQ:ETRM) has declined 90.67% since June 20, 2016 and is downtrending. It has underperformed by 107.37% the S&P500.

Analysts expect Helius Medical Technologies Inc (OTCMKTS:HSDT) to report $0.00 EPS on June, 26. The stock increased 1.37% or $0.02 on June 19, reaching $1.55. About 4,370 shares traded. Helius Medical Technologies Inc (OTCMKTS:HSDT) has 0.00% since June 20, 2016 and is . It has underperformed by 16.70% the S&P500.

Helius Medical Technologies, Inc. is a medical technology firm focused on neurological wellness. The company has market cap of $187.75 million. The Firm focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brain’s ability to heal itself. It currently has negative earnings. The Firm is engaged in the development of its product, the portable neuromodulation stimulator device.

EnteroMedics Inc. is a medical device company. The company has market cap of $32.57 million. The Firm is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. It currently has negative earnings. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: